What is the half-life of Trenbolone Hexahydrobenzylcarbonate in Parabol-100?

The half-life of Trenbolone Hexahydrobenzylcarbonate is approximately 14 days, based on ester-half-life pharmacokinetic modelling applied to the hexahydrobenzylcarbonate moiety. This contrasts sharply with Trenbolone Acetate at 1–3 days and Trenbolone Enanthate at 7–10 days, placing Parabol-100 in the longest-acting category within the trenbolone ester spectrum.

How does the release profile of Trenbolone Hexahydrobenzylcarbonate compare to shorter trenbolone esters?

The release profile is significantly flatter than that of short-acting esters. Trenbolone Hexahydrobenzylcarbonate reaches peak plasma concentration around days 4–7 post-injection, then declines gradually through day 14+. This sustained curve reduces injection-to-injection concentration variance, whereas Trenbolone Acetate produces sharper peaks and troughs requiring daily or every-other-day administration.

What injection frequency is recommended when using Parabol-100 for its pharmacokinetic benefits?

Twice-weekly injections are generally recommended to maintain stable plasma trenbolone levels within the therapeutic window, leveraging the ~14-day half-life. Some protocols use once-weekly administration, which remains pharmacokinetically viable due to the extended ester, though twice-weekly spacing keeps peak-to-trough ratios more consistent across the cycle duration.

Why are single-dose 1ml ampoules preferred over multi-dose vials for sterile injectable administration?

Single-dose 1ml ampoules eliminate repeated-entry contamination risk that multi-dose vials carry after each puncture. Each Parabol-100 ampoule is hermetically sealed, ensuring sterility until the moment of use. There is no need for benzyl alcohol as a bacteriostatic preservative, which can be irritating; the sealed format maintains pharmaceutical-grade sterility throughout its shelf life without additional antimicrobials.

How should Parabol-100 10x1ml ampoules be stored to preserve potency over a full cycle?

Parabol-100 ampoules should be stored at 15–25°C, away from direct light and moisture. Refrigeration is not required but should not exceed 30°C. Oil-based injectable solutions can develop harmless crystalline precipitation at low temperatures; gently warming the ampoule in the hand before use restores homogeneity without degrading the active compound. Always inspect for particulates before administration. (2) angle_used

Long-Acting Formula

BM Pharmaceuticals

Parabol-100 100mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Name: Parabol-100 100mg/ml 10x1ml Ampoules by BM Pharmaceuticals
Brand: BM Pharmaceuticals
SKU: INJ-THEX-BM-100-002
Price: 64.00 EUR
Availability: InStock

Parabol-100 is a single-dose injectable solution of Trenbolone Hexahydrobenzylcarbonate at 100mg/ml, distinguished by its extended pharmacokinetic profile — the hexahydrobenzylcarbonate ester delivers a sustained plasma half-life of approximately 14 days, enabling infrequent injection schedules without compromising hormonal stability. Ten individually sealed 1ml ampoules provide precise, contamination-free dosing across a full cycle. Each production batch undergoes HPLC-verified potency assay and LAL endotoxin testing; GMP certification governs the entire manufacturing chain at BM Pharmaceuticals' facility.

€64.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Sustained plasma trenbolone exposure over ~14 days per injection reduces dosing burden across the cycle.
Flat, stable release curve minimises peak-to-trough hormonal variance compared to short-ester trenbolone formats.
Non-aromatising compound eliminates oestrogen-mediated water accumulation as a cycle variable.
High androgen receptor binding affinity — approximately 5× that of testosterone — supports lean tissue retention during caloric restriction.
Ten hermetically sealed 1ml ampoules ensure single-use sterility for every injection in the pack.
HPLC-verified concentration guarantees the declared 100mg/ml potency is met in every BM Pharmaceuticals batch.
LAL endotoxin-tested manufacturing standard confirms injectable-grade safety at the batch level.

Phase	Dosage	Note
Introductory / Titration	100–150mg twice weekly	Allows plasma levels to build gradually over the first two half-lives (~14 days each); the extended ester means steady state is not reached until approximately 4–6 weeks — begin at the lower dose to assess individual tolerability before the compound accumulates.
Main Cycle	200–300mg twice weekly	Twice-weekly spacing (e.g. Mon/Thu) exploits the ~14-day half-life to maintain trough concentrations above threshold; higher frequencies add no pharmacokinetic benefit for this ester length.
Pre-Competition / Peak	200mg twice weekly (maintained)	The long half-life means dose reductions translate to plasma-level changes only after 2–3 weeks; plan dose tapering well in advance of competition date to control active compound levels at cut-off.
PCT Entry Timing	No compound, PCT begins 2–3 weeks post-last-injection	The ~14-day half-life requires a longer washout window before PCT initiation compared to short-ester trenbolone; initiating PCT too early will be counterproductive as plasma trenbolone remains suppressive.

Key takeaways

Expect a ~14-day plasma half-life from the hexahydrobenzylcarbonate ester.
Inject twice weekly to maintain stable trenbolone concentrations throughout your cycle.
Choose single-dose ampoules to eliminate repeated-puncture contamination risk.
Confirm concentration accuracy via BM Pharmaceuticals' HPLC batch testing.
Monitor progesterone-receptor activity during extended long-ester trenbolone cycles.

Trenbolone Hexahydrobenzylcarbonate: A Long Half-Life Defined by Ester Chemistry

Parabol-100 is a sterile oil-based injectable whose active moiety — Trenbolone Hexahydrobenzylcarbonate — achieves its prolonged pharmacokinetic window through the bulky cyclohexane ring structure of the attached ester, which slows enzymatic hydrolysis in depot tissue and sustains plasma trenbolone concentrations for roughly 14 days per injection (based on clinical ester half-life modelling). Compared to Trenbolone Acetate, whose half-life is approximately 1–3 days, the hexahydrobenzylcarbonate ester provides a release curve that is substantially flatter — peak concentrations are lower and trough concentrations are higher relative to mean AUC, which translates directly to reduced injection frequency and more stable hormonal background. Parabol-100 delivers active trenbolone at 100mg/ml through this extended esterification mechanism.

Release Profile and Injection Frequency

The hexahydrobenzylcarbonate ester governs a biphasic release pattern: an initial moderate Cmax is reached within approximately 4–7 days post-injection, followed by a slow declining phase extending to day 14 or beyond. This pharmacokinetic behaviour means that twice-weekly administration is generally sufficient to maintain plasma trenbolone above an effective threshold without the concentration spikes associated with short-ester variants. BM Pharmaceuticals formulates Parabol-100 in a pharmaceutical-grade oil vehicle to ensure consistent depot formation and predictable ester diffusion kinetics at the injection site.

Mechanism of Action and Systemic Activity

Trenbolone binds the androgen receptor with an affinity approximately five times greater than testosterone, as reported in receptor-binding studies using radioligand displacement assays. Trenbolone Hexahydrobenzylcarbonate does not aromatise to oestrogen, which eliminates oestrogen-mediated water retention as a confounding factor in body composition outcomes. The compound also binds the progesterone receptor with moderate affinity — a pharmacodynamic property relevant to side-effect monitoring during extended-release cycles where systemic exposure is prolonged by design.

Analytical Quality and Batch Integrity

Every BM Pharmaceuticals batch of Parabol-100 is tested by reverse-phase HPLC against a reference standard to confirm the declared 100mg/ml concentration within pharmacopoeial tolerances. LAL (Limulus Amebocyte Lysate) endotoxin testing verifies sterility at the injectable-product level. GMP-compliant manufacturing documentation links each ampoule to its production batch, allowing full traceability from API sourcing through fill-and-finish.

Usage

Calculate your injection schedule before opening the first ampoule — given Parabol-100's ~14-day half-life, map out twice-weekly injection days across the full cycle length to ensure consistent depot intervals.
Allow the ampoule to reach room temperature (approximately 20°C) before use; the oil vehicle flows more smoothly and depot formation is more uniform at body-adjacent temperature, supporting the predictable ester diffusion kinetics.
Snap the ampoule neck cleanly using a sterile gauze pad, then draw the full 1ml dose through a 18–21G drawing needle; switch to a 23–25G administration needle before injection to minimise tissue trauma.
Select a large muscle group — glutes or vastus lateralis — rotating sites each injection day to prevent depot accumulation and local irritation at a single site over the multi-week cycle.
Administer by slow intramuscular injection after aspirating; the extended-release ester forms an oil depot that releases trenbolone progressively — rapid injection does not accelerate release and increases local discomfort.
Log each injection date, site, and batch number; because the hexahydrobenzylcarbonate ester accumulates over successive injections, precise records allow you to calculate active plasma levels at any cycle point and time PCT entry accurately.

Warnings

Contraindications: Parabol-100 is contraindicated in individuals with known hypersensitivity to trenbolone or any oil-vehicle excipient, existing hepatic impairment, untreated cardiovascular disease including left ventricular hypertrophy, active prostate pathology, and during pregnancy or lactation. The long half-life means that adverse hormonal exposure cannot be rapidly reversed once administration has begun — contraindication screening before cycle initiation is therefore especially critical for this ester length.

Side Effects: Androgenic effects including accelerated scalp hair recession, acne vulgaris, and increased sebaceous gland activity are dose-dependent. Trenbolone's moderate progesterone-receptor affinity may contribute to gynecomastia in susceptible individuals even without oestrogen involvement. CNS-mediated effects such as insomnia, vivid dreaming, and mood volatility have been widely reported and may be exacerbated by the sustained plasma exposure characteristic of long-acting esters. Elevated haematocrit and changes in lipid fractions (HDL reduction, LDL increase) should be anticipated.

Monitoring: A comprehensive baseline panel including haematocrit, hepatic enzymes (ALT, AST), fasting lipid profile, blood pressure, and PSA (in males over 40) should be established before the first injection. Re-test at cycle midpoint and at washout; given the ~14-day half-life, residual hormonal activity persists for several weeks post-cycle, and monitoring should continue through this window. Cardiovascular parameters warrant particular attention during extended cycles.

PCT: Post-Cycle Therapy should not be initiated until approximately 2–3 weeks after the final Parabol-100 injection, allowing sufficient washout of the hexahydrobenzylcarbonate ester. Standard SERM-based PCT (e.g. tamoxifen or clomiphene) for 4–6 weeks is recommended to restore endogenous HPG axis function. The duration of PCT should reflect the degree of suppression associated with the full cycle length, which the long-acting ester extends relative to short-ester trenbolone protocols.

Frequently asked questions

What is the half-life of Trenbolone Hexahydrobenzylcarbonate in Parabol-100?: The half-life of Trenbolone Hexahydrobenzylcarbonate is approximately 14 days, based on ester-half-life pharmacokinetic modelling applied to the hexahydrobenzylcarbonate moiety. This contrasts sharply with Trenbolone Acetate at 1–3 days and Trenbolone Enanthate at 7–10 days, placing Parabol-100 in the longest-acting category within the trenbolone ester spectrum.
How does the release profile of Trenbolone Hexahydrobenzylcarbonate compare to shorter trenbolone esters?: The release profile is significantly flatter than that of short-acting esters. Trenbolone Hexahydrobenzylcarbonate reaches peak plasma concentration around days 4–7 post-injection, then declines gradually through day 14+. This sustained curve reduces injection-to-injection concentration variance, whereas Trenbolone Acetate produces sharper peaks and troughs requiring daily or every-other-day administration.
What injection frequency is recommended when using Parabol-100 for its pharmacokinetic benefits?: Twice-weekly injections are generally recommended to maintain stable plasma trenbolone levels within the therapeutic window, leveraging the ~14-day half-life. Some protocols use once-weekly administration, which remains pharmacokinetically viable due to the extended ester, though twice-weekly spacing keeps peak-to-trough ratios more consistent across the cycle duration.
Why are single-dose 1ml ampoules preferred over multi-dose vials for sterile injectable administration?: Single-dose 1ml ampoules eliminate repeated-entry contamination risk that multi-dose vials carry after each puncture. Each Parabol-100 ampoule is hermetically sealed, ensuring sterility until the moment of use. There is no need for benzyl alcohol as a bacteriostatic preservative, which can be irritating; the sealed format maintains pharmaceutical-grade sterility throughout its shelf life without additional antimicrobials.
How should Parabol-100 10x1ml ampoules be stored to preserve potency over a full cycle?: Parabol-100 ampoules should be stored at 15–25°C, away from direct light and moisture. Refrigeration is not required but should not exceed 30°C. Oil-based injectable solutions can develop harmless crystalline precipitation at low temperatures; gently warming the ampoule in the hand before use restores homogeneity without degrading the active compound. Always inspect for particulates before administration. (2) angle_used

Manufacturer

BM Pharmaceuticals' manufacturing capacity is most precisely characterised not by output volume alone, but by the technological infrastructure required to fill oil-based injectables at pharmaceutical grade across multiple ester variants simultaneously. Parabol-100 represents one of the technically demanding products on BM Pharmaceuticals' line: Trenbolone Hexahydrobenzylcarbonate is a viscous ester compound requiring controlled-temperature fill conditions, nitrogen-blanketed filling environments to prevent API oxidation, and precise volumetric fill accuracy per ampoule to guarantee the declared 100mg/ml concentration across an entire 10-ampoule carton. BM Pharmaceuticals' fill-and-finish equipment operates under ISO-classified cleanroom conditions, with particle monitoring and environmental sampling integrated into routine production runs rather than applied only at batch release. Capacity at this technological tier means the company can sustain parallel production of both aqueous and oil-based injectables without cross-contamination risk between lines — a facility-design requirement that necessitates dedicated equipment trains and validated cleaning procedures. Each oil-based batch, including Parabol-100, is subject to in-process viscosity and fill-weight checks that feed back into line control in real time, ensuring that ester concentration does not drift across a production run. This level of manufacturing infrastructure is the operational foundation behind the HPLC and LAL testing that certifies each batch at release.

Product details

Brand	BM Pharmaceuticals
Active ingredient	trenbolone hexahydrobenzylcarbonate
Also known as	Parabolan, Tren Hex, Trenbolone Hexa, Parabol-100, BM Pharmaceuticals Parabolan
Strength	100 mg
Form	Ampullen
Pack size	10 pieces
Item number	INJ-THEX-BM-100-002

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Parabolan 100mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Parabolan 100mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Parabolan by Balkan Pharmaceuticals is a pharmaceutical-grade injectable containing Trenbolone Hexahydrobenzylcarbonate at 100 mg/ml — a compound whose clinical origins trace back to the French pharmaceutical industry of the 1960s, making it one of the few anabolic steroids with a documented human-medicine approval history. Each 1 ml glass ampoule delivers a single, pre-measured dose of this long-acting trenbolone ester, preserving compound integrity from fill to injection. Batch release is governed by validated HPLC quantification and LAL endotoxin screening carried out under EU GMP Annex 1 conditions at Balkan Pharmaceuticals' Chișinău facility.

€58.00

High Concentration

Parabolan 100 100mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma Parabolan 100 delivers Trenbolone Hexahydrobenzylcarbonate at 100mg per millilitre across a 10ml vial — purpose-built for integration into structured modern cycle protocols where dosing precision and intra-cycle flexibility are non-negotiable. Its slow-release ester kinetics allow straightforward twice-weekly scheduling without the management overhead associated with shorter esters, making it a logical anchor compound in both bulking and recomposition phases. Quality is assured through batch-specific HPLC concentration verification and LAL endotoxin testing applied at the fill-and-finish stage of every production run.

€68.00

Brand Quality

Hexos 75mg/ml 10ml Vial by Driada Medical

Hexos by Driada Medical delivers Trenbolone Hexahydrobenzylcarbonate at 75mg per millilitre in a sterile 10ml multi-dose vial, engineered as the structural centrepiece of a periodised blast-and-cruise framework that demands precise hormonal control at every phase boundary. The 75mg/ml concentration gives practitioners a uniquely granular dosing unit — each 0.5ml increment equals 37.5mg — enabling stepwise escalation into a blast or progressive reduction toward cruise without the rounding compromises inherent to higher-concentration formats. Batch quality is enforced by Driada Medical through HPLC-confirmed potency verification, LAL endotoxin clearance, and full GMP-compliant manufacturing documentation traceable to the specific production lot.

€70.00

Pro Choice

Parabolan 75mg/ml 10ml Vial by Hilma Biocare

Hilma Biocare Parabolan supplies Trenbolone Hexahydrobenzylcarbonate at 75mg per millilitre in a sterile 10ml multi-dose vial — a concentration format chosen specifically for mature users who require incremental, tightly controlled dosing within supervised TRT-adjacent and hormone optimisation frameworks. The lower milligram-per-millilitre load allows conservative weekly titration steps that men over 40 typically benefit from when adding a high-affinity androgen alongside an established testosterone protocol. Batch release is subject to GMP-controlled criteria; HPLC potency confirmation and LAL endotoxin clearance are recorded at production level and retrievable by vial lot number.

€68.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00